Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

Ajay K. Nooka; Jonathan L. Kaufman; Cesar Rodriguez; Andrzej Jakubowiak; Yvonne Efebera; Brandi Reeves; Tanya Wildes; Sarah A. Holstein; Larry D. Anderson; Ashraf Badros; Leyla Shune; Ajai Chari; Huiling Pei; Annelore Cortoos; Sharmila Patel; J. Blake Bartlett; Jessica Vermeulen; Thomas S. Lin; Paul G. Richardson; Peter Voorhees

doi:10.1038/s41408-022-00653-1

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah A. Holstein, Larry D. Anderson, Ashraf Badros, Leyla Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, J. Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Paul G. Richardson, Peter Voorhees

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Article number	63
Journal	Blood Cancer Journal
Volume	12
Issue number	4
DOIs	https://doi.org/10.1038/s41408-022-00653-1
State	Published - Apr 2022

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-022-00653-1

Cite this

Nooka, A. K., Kaufman, J. L., Rodriguez, C., Jakubowiak, A., Efebera, Y., Reeves, B., Wildes, T., Holstein, S. A., Anderson, L. D., Badros, A., Shune, L., Chari, A., Pei, H., Cortoos, A., Patel, S., Bartlett, J. B., Vermeulen, J., Lin, T. S., Richardson, P. G., & Voorhees, P. (2022). Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer Journal, 12(4), Article 63. https://doi.org/10.1038/s41408-022-00653-1

Nooka, AK, Kaufman, JL, Rodriguez, C, Jakubowiak, A, Efebera, Y, Reeves, B, Wildes, T, Holstein, SA, Anderson, LD, Badros, A, Shune, L, Chari, A, Pei, H, Cortoos, A, Patel, S, Bartlett, JB, Vermeulen, J, Lin, TS, Richardson, PG & Voorhees, P 2022, 'Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN', Blood Cancer Journal, vol. 12, no. 4, 63. https://doi.org/10.1038/s41408-022-00653-1

@article{b5d0208a0a774841ae18096ea926b7c5,

title = "Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN",

author = "Nooka, {Ajay K.} and Kaufman, {Jonathan L.} and Cesar Rodriguez and Andrzej Jakubowiak and Yvonne Efebera and Brandi Reeves and Tanya Wildes and Holstein, {Sarah A.} and Anderson, {Larry D.} and Ashraf Badros and Leyla Shune and Ajai Chari and Huiling Pei and Annelore Cortoos and Sharmila Patel and Bartlett, {J. Blake} and Jessica Vermeulen and Lin, {Thomas S.} and Richardson, {Paul G.} and Peter Voorhees",

note = "Funding Information: We acknowledge the patients and investigators who participated in this study, in addition to the staff members at the study sites, the Data Review and Safety Monitoring Committees, Alliance Foundation Trials (AFT; https://acknowledgments.alliancefound.org [study AFT-29]), and the Janssen Team. We also acknowledge Daniela Hoehn, Yana Lutska, and Padma Bobba for their contributions to this study. This work was funded by Janssen Oncology. The study was sponsored by Janssen Oncology and designed in partnership with AFT. Editorial and medical writing support were provided by Laura Weber, PhD, of Cello Health Communications/MedErgy, and were funded by Janssen Global Services, LLC. Funding Information: We acknowledge the patients and investigators who participated in this study, in addition to the staff members at the study sites, the Data Review and Safety Monitoring Committees, Alliance Foundation Trials (AFT; https://acknowledgments.alliancefound.org [study AFT-29]), and the Janssen Team. We also acknowledge Daniela Hoehn, Yana Lutska, and Padma Bobba for their contributions to this study. This work was funded by Janssen Oncology. The study was sponsored by Janssen Oncology and designed in partnership with AFT. Editorial and medical writing support were provided by Laura Weber, PhD, of Cello Health Communications/MedErgy, and were funded by Janssen Global Services, LLC. ",

year = "2022",

month = apr,

doi = "10.1038/s41408-022-00653-1",

language = "English (US)",

volume = "12",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

AU - Nooka, Ajay K.

AU - Kaufman, Jonathan L.

AU - Rodriguez, Cesar

AU - Jakubowiak, Andrzej

AU - Efebera, Yvonne

AU - Reeves, Brandi

AU - Wildes, Tanya

AU - Holstein, Sarah A.

AU - Anderson, Larry D.

AU - Badros, Ashraf

AU - Shune, Leyla

AU - Chari, Ajai

AU - Pei, Huiling

AU - Cortoos, Annelore

AU - Patel, Sharmila

AU - Bartlett, J. Blake

AU - Vermeulen, Jessica

AU - Lin, Thomas S.

AU - Richardson, Paul G.

AU - Voorhees, Peter

N1 - Funding Information: We acknowledge the patients and investigators who participated in this study, in addition to the staff members at the study sites, the Data Review and Safety Monitoring Committees, Alliance Foundation Trials (AFT; https://acknowledgments.alliancefound.org [study AFT-29]), and the Janssen Team. We also acknowledge Daniela Hoehn, Yana Lutska, and Padma Bobba for their contributions to this study. This work was funded by Janssen Oncology. The study was sponsored by Janssen Oncology and designed in partnership with AFT. Editorial and medical writing support were provided by Laura Weber, PhD, of Cello Health Communications/MedErgy, and were funded by Janssen Global Services, LLC. Funding Information: We acknowledge the patients and investigators who participated in this study, in addition to the staff members at the study sites, the Data Review and Safety Monitoring Committees, Alliance Foundation Trials (AFT; https://acknowledgments.alliancefound.org [study AFT-29]), and the Janssen Team. We also acknowledge Daniela Hoehn, Yana Lutska, and Padma Bobba for their contributions to this study. This work was funded by Janssen Oncology. The study was sponsored by Janssen Oncology and designed in partnership with AFT. Editorial and medical writing support were provided by Laura Weber, PhD, of Cello Health Communications/MedErgy, and were funded by Janssen Global Services, LLC.

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85128316769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128316769&partnerID=8YFLogxK

U2 - 10.1038/s41408-022-00653-1

DO - 10.1038/s41408-022-00653-1

M3 - Letter

C2 - 35418120

AN - SCOPUS:85128316769

SN - 2044-5385

VL - 12

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 4

M1 - 63

ER -

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this